Skip to Content

Breast-Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy


SWOG S1007 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and Her-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

The purpose of this study is to find out if the Oncotype DX® Recurrence Score can help decide whether patients should receive chemotherapy or not.  This study is being done in patients with lower Recurrence Scores (25 or less).

Recurrence Score: The Oncotype DX® is a test that looks at multiple genes related to breast cancer. The combination of the test results produces a score that is useful in guiding treatment choices for patients with node-negative breast cancer. The higher the score is, the more likely that the patient’s breast cancer will come back after surgery.

Rebecca Denofer, RN, OCN at 802-747-1692

Rutland Regional Medical Center
160 Allen Street
Rutland, VT 05701

Facebook YouTube LinkedIn CarePages Twitter